MedTrace Logo

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

NCT01128842 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

Neratinib

240 mg once daily by mouth.

DRUG

Capecitabine

1500 mg/m\^2 twice daily by mouth.

Sponsors & Collaborators

  • Puma Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Puma · Biotechnology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128842 on ClinicalTrials.gov